Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061685 | 0.75 | PDK1 (0.32) | BRD4 | |
| SCHEMBL10061679 | 0.74 | CXCR4 (0.41) | POLBKDM4E | |
| SCHEMBL24914012 | 0.70 | PNMT (0.44) | POLBNSD2KAT2BEZH2 | |
| Hydrochloric Acid SCHEMBL31062565 | 0.69 | PNMT (0.43) | POLBNSD2EZH2 | |
| SCHEMBL11104244 | 0.68 | POLB (0.47) | POLBNSD2BRD4KAT2BCYP3A4 | |
| SCHEMBL6925611 | 0.68 | KDM4E (0.61) | POLBNSD2BRD4KAT2BCYP3A4 | |
| SCHEMBL10061741 | 0.67 | POLB (0.48) | POLBBRD4ATAD2RET | |
| SCHEMBL26268468 | 0.66 | POLB (0.49) | POLBNSD2BRD4KAT2BCYP3A4 | |
| SCHEMBL24914013 | 0.65 | PNMT (0.41) | NSD2KAT2B | |
| SCHEMBL2674423 | 0.65 | POLB (0.47) | POLBNSD2BRD4KAT2BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | POLB 2013/4885NSD2 1544/4885PIK3CA 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.